Clinical Trials

    Showing 1 - 4 of 4 ovarian

    A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum (GOG-3026)

    Status: Open Not Enrolling

    Investigator: Aparna Kamat

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum.... Read more >

    A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

    Status: Enrolling

    Investigator: Aparna Kamat

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.... Read more >

    Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

    Status: Enrolling

    Investigator: Pedro Ramirez

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemothera... Read more >

    Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

    Status: Enrolling

    Investigator: Monisha Singh

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by b... Read more >